Хайлтын үр дүнгүүд - Haiyi Jiang

  • 20-н 1 - 20 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Diagnosis and management of drug-associated interstitial lung disease

    Diagnosis and management of drug-associated interstitial lung disease -н Néstor L. Müller, Dorothy A. White, Haiyi Jiang, Akihiko Gemma

    Хэвлэсэн 2004
    Бүрэн текст авах Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

    Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-s... -н Suresh Senan, Isamu Okamoto, Gyeong‐Won Lee, Yuanbin Chen, Seiji Niho, Gabriel Mak, Wenliang Yao, Norah J. Shire, Haiyi Jiang, Byoung Chul Cho

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients

    Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na^|^iuml;ve NSCLC Patients -н Miyako Satouchi, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Nobuyuki Yamamoto, Nobuyuki Katakami, Kazuhiko Nakagawa, Katsuyuki Kiura, Haiyi Jiang, Tony Mok, Nagahiro Saijo, Masahiro Fukuoka

    Хэвлэсэн 2012
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

    A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer -н Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang, Kazuto Nishio, Nagahiro Saijo, Masahiro Fukuoka

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

    57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expans... -н Don L. Gibbons, Laura Q.M. Chow, Dong‐Wook Kim, Seung‐Whan Kim, Tammie C. Yeh, Xuyang Song, Haiyi Jiang, Rosemary Taylor, Joyson Karakunnel, Ben Creelan

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

    Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cance... -н Kōichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Y. Itoh, Haiyi Jiang, Emma Duffield, Rose McCormack, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

    A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors -н Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Haruyasu Murakami, Atsushi Horiike, Yasuhito Fujisaka, Tetsu Shinkai, Makoto Tahara, Kenji Kawada, Hiromichi Ebi, Yasutsuna Sasaki, Haiyi Jiang, Nagahiro Saijo

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

    Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report -н Yuanbin Chen, Luis Paz‐Ares, Niels Reinmuth, Marina Chiara Garassino, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Francesco Verderame, Libor Havel, György Losonczy, Nikolay Conev, Katsuyuki Hotta, Jun Ho Ji, Stuart Spencer, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer -н Riichiroh Maruyama, Yutaka Nishiwaki, Tomohide Tamura, Nobuyuki Yamamoto, Masahiro Tsuboi, Kazuhiko Nakagawa, Tetsu Shinkai, Shunichi Negoro, Fumio Imamura, Kenji Eguchi, Koji Takeda, Akira Inoue, Keisuke Tomii, Masao Harada, Noriyuki Masuda, Haiyi Jiang, Y. Itoh, Yukito Ichinose, Nagahiro Saijo, Masahiro Fukuoka

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected P... -н Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

    Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma -н Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, James Chih‐Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma Duffield, Claire Watkins, Alison Armour, Masahiro Fukuoka

    Хэвлэсэн 2009
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)

    PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC) -н Liyan Jiang, Xinying Su, Tianwei Zhang, Xiaolu Yin, Meizhuo Zhang, Haihua Fu, Hulin Han, Yun Sun, Lili Dong, Jialin Qian, Yanhua Xu, Xuan Fu, Paul R. Gavine, Yanbin Zhou, Kun Tian, Jiaqi Huang, Dong Shen, Haiyi Jiang, Yihong Yao, Baohui Han, Yi Gu

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

    PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN -н Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Олександр Войтко, Libor Havel, Artem Poltoratskiy, György Losonczy, Niels Reinmuth, Yashaswi Shrestha, Nikunj Patel, Helen Mann, Haiyi Jiang, Mustafa Özgüroğlu, Yuanbin Chen

    Хэвлэсэн 2019
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled... -н Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen, Mustafa Özgüroğlu, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Олександр Войтко, Libor Havel, Artem Poltoratskiy, György Losonczy, Niels Reinmuth, Nikunj Patel, Peter J. Laud, Norah J. Shire, Haiyi Jiang, Luis Paz‐Ares

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

    Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN -н Luis Paz‐Ares, Y Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Олександр Войтко, Artem Poltoratskiy, E. Musso, Libor Havel, Igor Bondarenko, György Losonczy, Nikolay Conev, Helen Mann, Tapashi Dalvi, Haiyi Jiang, Jonathan W. Goldman

    Хэвлэсэн 2022
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study

    Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study -н Mingchao Xie, Miljenka Vuko, Jaime Rodriguez‐Canales, Johannes Zimmermann, Markus Schick, Cathy O’Brien, Luis Paz‐Ares, Jonathan W. Goldman, Marina Chiara Garassino, Carl M. Gay, John V. Heymach, Haiyi Jiang, J. Carl Barrett, Ross Stewart, Zhongwu Lai, Lauren A. Byers, Charles M. Rudin, Yashaswi Shrestha

    Хэвлэсэн 2024
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches

    Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches -н Aaron M. Udager, Ting‐yu Liu, Stephanie L. Skala, Martin J. Magers, Andrew S. McDaniel, Daniel E. Spratt, Felix Y. Feng, Jawed A. Siddiqui, Xu Cao, Kristina Fields, Todd M. Morgan, Ganesh S. Palapattu, Alon Z. Weizer, Arul M. Chinnaiyan, Ajjai Alva, Jeffery S. Montgomery, Scott A. Tomlins, Haiyi Jiang, Ranee Mehra

    Хэвлэсэн 2016
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

    Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden -н Luis Paz‐Ares, Marina Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian J. Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan W. Goldman

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial

    Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial -н Solange Peters, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, К. К. Лактионов, Dmytro Trukhin, Sang‐We Kim, G Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Caitlin D. Lowery, Helen Mann, Ross Stewart, Haiyi Jiang, Edward B. Garon, Tony Mok, Melissa L. Johnson

    Хэвлэсэн 2024
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer -н Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: